{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:52:03Z","timestamp":1789469523558,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100027043","name":"Milken Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022974","name":"Global Alliance for Chronic Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022974","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jad.2025.04.119","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:41:26Z","timestamp":1745325686000},"page":"438-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review"],"prefix":"10.1016","volume":"382","author":[{"given":"Morgan C.H.","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Dri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Ballum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.04.119_bb0005","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40263-023-01032-5","article-title":"Dextromethorphan-bupropion for the treatment of depression: a systematic review of efficacy and safety in clinical trials","volume":"37","author":"Akbar","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2025.04.119_bb0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4088\/JCP.17m11725","article-title":"Direct and indirect cost burden and change of employment status in treatment-resistant depression","volume":"79","author":"Amos","year":"2018","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jad.2025.04.119_bb0015","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1056\/NEJMc2308757","article-title":"Ketamine versus ECT for nonpsychotic treatment-resistant major depression","volume":"389","author":"Anand","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2025.04.119_bb0020","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.jad.2025.04.119_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.psycom.2024.100177","article-title":"A real-world study examining the impact of esketamine nasal spray in people living with major depressive disorder in Australia and New Zealand","volume":"4","author":"Hopwood","year":"2024","journal-title":"Psychiatr. Res. Commun."},{"key":"10.1016\/j.jad.2025.04.119_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.31887\/DCNS.2014.16.2\/rcohen","article-title":"Patient-reported outcomes before and after treatment of major depressive disorder","volume":"16","author":"IsHak","year":"2014","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jad.2025.04.119_bb0035","series-title":"Assessment of Health-Related Quality of Life and Health Status in Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray plus an Oral Antidepressant","first-page":"21","author":"Jamieson","year":"2023"},{"key":"10.1016\/j.jad.2025.04.119_bb0040","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1007\/s11136-023-03451-9","article-title":"Effects of Esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (Aspire I and aspire II)","volume":"32","author":"Jamieson","year":"2023","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.jad.2025.04.119_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109299","article-title":"The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression","volume":"223","author":"Jawad","year":"2023","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.jad.2025.04.119_bb0050","doi-asserted-by":"crossref","first-page":"70","DOI":"10.9758\/cpn.2022.20.1.70","article-title":"Long-term safety and efficacy of esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression\u2013 an Asian sub-group analysis from the SUSTAIN-2 study","volume":"20","author":"Jeon","year":"2022","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.jad.2025.04.119_bb0055","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jad.2024.01.084","article-title":"Long-term quality of life after repeated ketamine infusions in anxious and nonanxious patients with depression","volume":"349","author":"Liang","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.04.119_bb0060","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40263-024-01114-y","article-title":"Glutamatergic modulators for major depression from theory to clinical use","volume":"38","author":"McIntyre","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2025.04.119_bb0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jad.2020.07.045","article-title":"Burden of treatment resistant depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: economic burden and healthcare resource utilization","volume":"277","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.04.119_bb0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.04.119_bb0075","first-page":"6","article-title":"Patient-reported outcome measures for life engagement in mental health: a systematic review","author":"McIntyre","year":"2022","journal-title":"J. Patient Rep. Outcom."},{"key":"10.1016\/j.jad.2025.04.119_bb0080","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2025.04.119_bb0085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euroneuro.2024.05.009","article-title":"Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression","volume":"85","author":"McIntyre","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.04.119_bb0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jad.2021.06.032","article-title":"Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: a systematic review","volume":"293","author":"Ng","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.04.119_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115378","article-title":"Predicting outcome with intranasal esketamine treatment: a machine-learning, three-month study in treatment-resistant depression (ESK-learning)","volume":"327","author":"Pettorruso","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2025.04.119_bb0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40271-013-0036-x","article-title":"Validity and reliability of the Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument","volume":"7","author":"Richardson","year":"2014","journal-title":"Patient"},{"key":"10.1016\/j.jad.2025.04.119_bb0105","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2174\/1570159X12666140619204251","article-title":"The role of ketamine in treatment-resistant depression: a systematic review","volume":"12","author":"Serafini","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jad.2025.04.119_bb0110","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jad.2025.04.119_bb0115","author":"U.S Food and Drug Administration"},{"key":"10.1016\/j.jad.2025.04.119_bb0120","first-page":"140","article-title":"World Health Organization Quality-of-Life Scale (WHOQOL-BREF): analyses of their item response theory properties based on the graded responses model","volume":"5","author":"Vahedi","year":"2010","journal-title":"Iran. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.04.119_bb0125","first-page":"12","article-title":"Improving quality of life for patients with major depressive disorder using future-directed therapy","volume":"10","author":"Vilhauer","year":"2013","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.jad.2025.04.119_bb0130","author":"Wells"},{"key":"10.1016\/j.jad.2025.04.119_bb0135","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jad.2024.04.086","article-title":"Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: a systematic review and meta-analysis","volume":"356","author":"Wong","year":"2024","journal-title":"J. Affect. Disord."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725006949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725006949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:48:03Z","timestamp":1778244483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725006949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":27,"alternative-id":["S0165032725006949"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.04.119","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.04.119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}